changes in protein profiles in bortezomib applied multiple myeloma ...

LIST OF FIGURES
Figure Page
Figure 1.1. Loss of Normal Growth Control .................................................................. 3
Figure 1.2. Development of Cancer ................................................................................ 4
Figure 1.3. The Activation and Differentiation of B Cell ............................................... 5
Figure 1.4. Function of the Plasma Cells ........................................................................ 6
Figure 1.5. Molecular Structure of Immunoglobulin ...................................................... 7
Figure 1.6. Tumor-micro environmental Interactions in MM ...................................... 12
Figure 1.7. Structure of Bortezomib ............................................................................. 19
Figure 1.8. Scheme of the 26S Proteasome .................................................................. 20
Figure 1.9. Cross Section of β Ring .............................................................................. 21
Figure 1.10. Ubiquitin–Proteasome Pathway (UPP) ...................................................... 22
Figure 1.11. The inhibition of NF-κB activation. ........................................................... 23
Figure 1.12. Effect of Bortezomib on Various Growth and Survival Pathways in MM 24
Figure 2.1. Biochemical Interactions Between Genomics and Proteomics .................. 25
Figure 2.2. Schematic of workflow involved in a proteomics experiment, Bio-rad. .... 26
Figure 2.3. Reaction of polyacrylamide gel formation ................................................. 31
Figure 2.4. Schematic Representation of 2D PAGE ..................................................... 33
Figure 2.5. Schematic Representation of In-Gel Digestion .......................................... 36
Figure 2.6. Basic Components of a Mass Spectrometer, Premier Biosoft. ................... 37
Figure 2.7. Illustration of the principles behind MALDI ............................................. 40
Figure 2.8. Schematic representation of Reflectron Time-of-Flight Mass Analyzer ... 41
Figure 2.9. A MALDI-TOF Mass Spectrometer .......................................................... 42
Figure 2.10. A Mass Spectrometer (Representation of the most suitable
source-analyzer-dedector combination) .................................................... 42
Figure 3.1. The Dosage of Bortezomib (nM) Applied on MM U-266 Cells ................. 48
Figure 3.2. Apoptosis: The Extrinsic and Intrinsic Pathways ........................................ 51
Figure 3.3. Aplied Bortezomib Doses on U-266 Cells
for Caspase-3 Enzyme Activity ................................................................. 52
Figure 3.4. Bradford Assay ............................................................................................ 55
Figure 3.5. Aplied Bortezomib Doses on U-266 Cells
for Dedection of Loss of MMP .............................................................................. 56
ix